Project Details
Status | Active |
---|---|
Effective start/end date | 18/10/2021 → 17/10/2025 |
Collaborative partners
- King's College London (lead)
- Novo Nordisk A/S
- Maze Therapeutics, Inc.
- Merck Sharp & Dohme Corp
- Bristol-Myers Squibb Company
- GSK Glaxo Wellcome Research & Development Ltd
- Takeda Pharmaceuticals International
- Pfizer Inc.
- AstraZeneca AB
Funding
- Queen Mary University of London: £958,231.00